Antinociceptive effect of bupropion on visceral pain and its mechanism of action

İsa Yeşilyurt; Özge Darakcı Saltık; Ayhan Bozkurt

Makale detayları

Antinociceptive effect of bupropion on visceral pain and its mechanism of action

Yazarlar:

İsa Yeşilyurt | Özge Darakcı Saltık | Ayhan Bozkurt

Yayıncı:

Cukurova University

Ana Başlıklar:

Duyusal Sistemler

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.415-423

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320790

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 PPurpose: Bupropion is an antidepressant that inhibits noradrenaline and dopamine reuptake. In the current scientific literature, there is limited information regarding the effects of bupropion on pain, predominantly derived from somatic pain studies. This study aims to investigate the impact of bupropion for the first time in visceral pain induced by colorectal distension, a pure visceral pain model, and to reveal the role of various receptors involved in pain control in this effect. Materials and Methods: Male Sprague-Dawley rats were used in the study. Visceral pain was assessed by colorectal distension-induced visceromotor response. Bupropion is administered gastrically at 5, 10, 20, and 40 mgkg doses. The mechanism of action of bupropion at the spinal cord level was investigated by intrathecal administration of antagonists of α1 and α2 adrenoceptors prazosin and yohimbine, D1 and D2 dopamine SCH 23390 and sulpiride and opioid receptors naloxone 10 minutes before bupropions effective dose. Results: Bupropion showed significant antinociceptive effects at 20 and 40 mgkg intragastric doses; no difference was found between these two doses. Intrathecally administered yohimbine 30 µgrats, sulpiride 30 µgrats, i.t., and naloxone 2.5 µgrats diminished the antinociceptive effect of bupropion. Prazosin and SCH 23390 did not alter bupropions effect. Conclusion: The findings show the antinociceptive effect of bupropion in visceral pain, and adrenergic, dopaminergic, and opioidergic receptors in the spinal cord play a role in this effect.

 PPurpose: Bupropion is an antidepressant that inhibits noradrenaline and dopamine reuptake. In the current scientific literature, there is limited information regarding the effects of bupropion on pain, predominantly derived from somatic pain studies. This study aims to investigate the impact of bupropion for the first time in visceral pain induced by colorectal distension, a pure visceral pain model, and to reveal the role of various receptors involved in pain control in this effect. Materials and Methods: Male Sprague-Dawley rats were used in the study. Visceral pain was assessed by colorectal distension-induced visceromotor response. Bupropion is administered gastrically at 5, 10, 20, and 40 mgkg doses. The mechanism of action of bupropion at the spinal cord level was investigated by intrathecal administration of antagonists of α1 and α2 adrenoceptors prazosin and yohimbine, D1 and D2 dopamine SCH 23390 and sulpiride and opioid receptors naloxone 10 minutes before bupropions effective dose. Results: Bupropion showed significant antinociceptive effects at 20 and 40 mgkg intragastric doses; no difference was found between these two doses. Intrathecally administered yohimbine 30 µgrats, sulpiride 30 µgrats, i.t., and naloxone 2.5 µgrats diminished the antinociceptive effect of bupropion. Prazosin and SCH 23390 did not alter bupropions effect. Conclusion: The findings show the antinociceptive effect of bupropion in visceral pain, and adrenergic, dopaminergic, and opioidergic receptors in the spinal cord play a role in this effect.

 PPurpose: Bupropion is an antidepressant that inhibits noradrenaline and dopamine reuptake. In the current scientific literature, there is limited information regarding the effects of bupropion on pain, predominantly derived from somatic pain studies. This study aims to investigate the impact of bupropion for the first time in visceral pain induced by colorectal distension, a pure visceral pain model, and to reveal the role of various receptors involved in pain control in this effect. Materials and Methods: Male Sprague-Dawley rats were used in the study. Visceral pain was assessed by colorectal distension-induced visceromotor response. Bupropion is administered gastrically at 5, 10, 20, and 40 mgkg doses. The mechanism of action of bupropion at the spinal cord level was investigated by intrathecal administration of antagonists of α1 and α2 adrenoceptors prazosin and yohimbine, D1 and D2 dopamine SCH 23390 and sulpiride and opioid receptors naloxone 10 minutes before bupropions effective dose. Results: Bupropion showed significant antinociceptive effects at 20 and 40 mgkg intragastric doses; no difference was found between these two doses. Intrathecally administered yohimbine 30 µgrats, sulpiride 30 µgrats, i.t., and naloxone 2.5 µgrats diminished the antinociceptive effect of bupropion. Prazosin and SCH 23390 did not alter bupropions effect. Conclusion: The findings show the antinociceptive effect of bupropion in visceral pain, and adrenergic, dopaminergic, and opioidergic receptors in the spinal cord play a role in this effect.

 Amaç: Bupropion, noradrenalin ve dopamin geri alımını inhibe eden bir antidepresandır. Bilimsel literatürde, bupropionun ağrı üzerindeki etkilerine ilişkin sınırlı bilgi bulunmaktadır ve bu bilgiler ağırlıklı olarak somatik ağrı çalışmalarından elde edilmiştir. Bu çalışmanın amacı, ilk kez olarak pür viseral ağrı modeli olan kolorektal distansiyon ile indüklenen viseral ağrıda bupropionun etkisini araştırmak ve bu etkide ağrı kontrolünde rol alan çeşitli reseptörlerin rolünü ortaya koymaktır. Gereç ve Yöntem: Çalışmada erkek Sprague-Dawley sıçanlar kullanıldı. Viseral ağrı, kolorektal distansiyon ile indüklenen viseromotor yanıt ile değerlendirildi. Bupropion 5, 10, 20, 40 mgkg dozlarında gastrik olarak uygulandı. Bupropionun omurilik seviyesindeki etki mekanizması, α1 ve α2 adrenoseptörlerinin, D1 ve D2 dopamin ve opioid reseptörlerinin antagonistlerinin bupropionun etkili dozundan 10 dakika önce intratekal olarak uygulanmasıyla araştırıldı. Bulgular: Bupropion 20 ve 40 mgkg intragastrik dozlarda anlamlı antinosiseptif etki göstermiş, bu iki doz arasında fark bulunmamıştır. İntratekal olarak uygulanan yohimbin 30 µgsıçan, sülpirid 30 µg sıçan, i.t. ve nalokson 2,5 µgsıçan bupropionun antinosiseptif etkisini azaltmıştır. Prazosin ve SCH 23390 bupropionun etkisini değiştirmemiştir. Sonuç: Bulgular bupropionun visseral ağrıda antinosiseptif etkisini ve bu etkide omurilikteki adrenerjik, dopaminerjik ve opioiderjik reseptörlerin rol oynadığını göstermektedir.

Makale detayları

Antinociceptive effect of bupropion on visceral pain and its mechanism of action

Yazarlar:

İsa Yeşilyurt | Özge Darakcı Saltık | Ayhan Bozkurt

Yayıncı:

Cukurova University

Ana Başlıklar:

Duyusal Sistemler

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.415-423

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320790

pISSN:

2602-3032

Antidepressant

Bupropion

visceral

pain

visceromotorAntidepresan

Bupropion

viiseral

ağrı

viseromotor

Sayı

Makale detayları

Yazarlar: İsa Yeşilyurt | Özge Darakcı Saltık | Ayhan Bozkurt

Yayıncı: Cukurova University

Ana Başlıklar: Duyusal Sistemler

Dergi: Cukurova Medical Journal Vol.49 Issue 2, pp.415-423

Belge Tipi: Makale

Yayın Tarihi: 6/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001320790

pISSN: 2602-3032

Sayı

Yazarlar:

İsa Yeşilyurt | Özge Darakcı Saltık | Ayhan Bozkurt

Yayıncı:

Cukurova University

Ana Başlıklar:

Duyusal Sistemler

Dergi:

Cukurova Medical Journal Vol.49 Issue 2, pp.415-423

Belge Tipi:

Makale

Yayın Tarihi:

6/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001320790

pISSN:

2602-3032